U.S. License Holder:
Novartis Pharms. Corp.
Date of License:
COSENTYX (secukinumab) is a human interleukin-17A antagonist indicated for the treatment of:
Moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy;
Adults with active psoriatic arthritis (PsA);
Adults with active ankylosing spondylitis (AS);
Adults with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation.